These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 18754077)

  • 1. Antiviral activity of cidofovir against telomerase-specific replication-selective oncolytic adenovirus, OBP-301 (Telomelysin).
    Ouchi M; Kawamura H; Urata Y; Fujiwara T
    Invest New Drugs; 2009 Jun; 27(3):241-5. PubMed ID: 18754077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
    Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T
    Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells.
    Watanabe Y; Hashimoto Y; Kagawa S; Kawamura H; Nagai K; Tanaka N; Urata Y; Fujiwara T
    Cancer Gene Ther; 2012 Nov; 19(11):767-72. PubMed ID: 22956040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD').
    Taki M; Kagawa S; Nishizaki M; Mizuguchi H; Hayakawa T; Kyo S; Nagai K; Urata Y; Tanaka N; Fujiwara T
    Oncogene; 2005 Apr; 24(19):3130-40. PubMed ID: 15735729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The hTERT promoter enhances the antitumor activity of an oncolytic adenovirus under a hypoxic microenvironment.
    Hashimoto Y; Tazawa H; Teraishi F; Kojima T; Watanabe Y; Uno F; Yano S; Urata Y; Kagawa S; Fujiwara T
    PLoS One; 2012; 7(6):e39292. PubMed ID: 22720091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer model.
    Huang P; Watanabe M; Kaku H; Kashiwakura Y; Chen J; Saika T; Nasu Y; Fujiwara T; Urata Y; Kumon H
    Cancer Gene Ther; 2008 May; 15(5):315-22. PubMed ID: 18274558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effects of telomerase-specific replication-selective oncolytic viruses for adenoid cystic carcinoma cell lines.
    Sato D; Kurihara Y; Kondo S; Shirota T; Urata Y; Fujiwara T; Shintani S
    Oncol Rep; 2013 Dec; 30(6):2659-64. PubMed ID: 24065118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy.
    Fujiwara T; Kagawa S; Kishimoto H; Endo Y; Hioki M; Ikeda Y; Sakai R; Urata Y; Tanaka N; Fujiwara T
    Int J Cancer; 2006 Jul; 119(2):432-40. PubMed ID: 16477640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic and therapeutic application of telomerase-specific oncolytic adenoviral agents.
    Fujiwara T; Urata Y; Tanaka N
    Front Biosci; 2008 Jan; 13():1881-6. PubMed ID: 17981675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cidofovir Diphosphate Inhibits Adenovirus 5 DNA Polymerase via both Nonobligate Chain Termination and Direct Inhibition, and Polymerase Mutations Confer Cidofovir Resistance on Intact Virus.
    Chamberlain JM; Sortino K; Sethna P; Bae A; Lanier R; Bambara RA; Dewhurst S
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telomerase-specific replication-selective virotherapy for human cancer.
    Kawashima T; Kagawa S; Kobayashi N; Shirakiya Y; Umeoka T; Teraishi F; Taki M; Kyo S; Tanaka N; Fujiwara T
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):285-92. PubMed ID: 14734481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter.
    Fujiwara T; Urata Y; Tanaka N
    Curr Cancer Drug Targets; 2007 Mar; 7(2):191-201. PubMed ID: 17346111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro analysis of cidofovir and genetically engineered TK expression as potential approaches for the intervention of ColoAd1-based treatment of cancer.
    Bauzon M; Jin F; Kretschmer P; Hermiston T
    Gene Ther; 2009 Sep; 16(9):1169-74. PubMed ID: 19458647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic interaction of telomerase-specific oncolytic virotherapy and chemotherapeutic agents for human cancer.
    Fujiwara T; Kagawa S; Tazawa H
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1809-16. PubMed ID: 21740362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced suppression of adenovirus replication by triple combination of anti-adenoviral siRNAs, soluble adenovirus receptor trap sCAR-Fc and cidofovir.
    Pozzuto T; Röger C; Kurreck J; Fechner H
    Antiviral Res; 2015 Aug; 120():72-8. PubMed ID: 26026665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examination of the optimal condition on the in vitro sensitivity to telomelysin in head and neck cancer cell lines.
    Sakakibara A; Tsukuda M; Kondo N; Ishiguro Y; Kimura M; Fujita K; Takahashi H; Matsuda H
    Auris Nasus Larynx; 2011 Oct; 38(5):589-99. PubMed ID: 21362583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical evaluation of differentially targeting dual virotherapy for human solid cancer.
    Sakai R; Kagawa S; Yamasaki Y; Kojima T; Uno F; Hashimoto Y; Watanabe Y; Urata Y; Tanaka N; Fujiwara T
    Mol Cancer Ther; 2010 Jun; 9(6):1884-93. PubMed ID: 20501801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro.
    Williams-Aziz SL; Hartline CB; Harden EA; Daily SL; Prichard MN; Kushner NL; Beadle JR; Wan WB; Hostetler KY; Kern ER
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3724-33. PubMed ID: 16127046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced inhibition of parvovirus B19 replication by cidofovir in extendedly exposed erythroid progenitor cells.
    Bonvicini F; Bua G; Manaresi E; Gallinella G
    Virus Res; 2016 Jul; 220():47-51. PubMed ID: 27071853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro.
    Keith KA; Wan WB; Ciesla SL; Beadle JR; Hostetler KY; Kern ER
    Antimicrob Agents Chemother; 2004 May; 48(5):1869-71. PubMed ID: 15105146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.